We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Proteomic Test Stratifies Patients for Immunotherapies

By LabMedica International staff writers
Posted on 28 Dec 2016
Print article
Image: Sample application for the VeriStrat proteomic serum test for advanced non-small-cell lung cancer which helps physicians determine whether a patient should receive treatment with an epidermal growth factor receptor inhibitor (Photo courtesy of Biodesix).
Image: Sample application for the VeriStrat proteomic serum test for advanced non-small-cell lung cancer which helps physicians determine whether a patient should receive treatment with an epidermal growth factor receptor inhibitor (Photo courtesy of Biodesix).
Anti PD-1 inhibitors are the treatments of choice in second line non-small cell lung cancer (NSCLC), however they only benefit a fraction of patients, while existing biomarkers such as PD-L1 expression correlate with outcomes, but are not sufficient to guide therapy.

A serum-based test, BDX008, utilizing mass spectrometry was developed to assist in treatment selection for melanoma patients being considered for nivolumab. The possible role of BDX008 in NSCLC patients treated with nivolumab was evaluated and additionally, the role of the commercially available VeriStrat test, known to have prognostic and predictive roles in NSCLC2, was investigated in nivolumab-treated patients for the first time.

Scientists at the National Institute for Cancer Research (Genova, Italy) collaborating with those at Biodesix, Inc (Boulder, CO, USA) enrolled previously treated patients with advanced NSCLC (both squamous and non-squamous histology) in a single-institution translational study. Patients in the study were treated with nivolumab, an anti-PD-1 agent, and serum samples were evaluated using both an investigational test developed for use in melanoma, and with the Biodesix VeriStrat testing.

Spectra were collected from pre-treatment serum samples on matrix-assisted laser desorption/ionization (MALDI) time of flight mass spectrometer using standard VeriStrat acquisition procedures or “deep MALDI” approach for BDX008 testing. The BDX008 test generates a classification of positive (BDX008+, good outcomes) or negative (BDX008-, poor outcomes); VeriStrat classifies samples as VeriStrat Good (VS Good) or VeriStrat Poor (VS Poor).

The team reported that no correlations were found between objective response or disease control rates and BDX008 or VeriStrat tests by any of the response definition. Early death (ED), defined as death before the first radiological assessment, during 1-4 cycles, occurred in 10 patients (26.3%) classified as BDX008- versusone patient (4.6%) classified as BDX008+. By VeriStrat, ED occurred in two patients (5.4%) classified as VS Good and nine patients (39.1%) classified as VS Poor.

David Brunel, Chief Executive Officer of Biodesix, said, “Our testing methodology, which measures hundreds of proteins in a single assay and then utilizes the machine learning intelligence of our Diagnostic Cortex is uniquely suited to characterizing different immune states and tumor immune escape strategies over time, with the goal of enabling physicians to provide advanced precision medicine.” The study was presented at the 17th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer held December 4-7, 2016, in Vienna, Austria.

Related Links:
National Institute for Cancer Research
Biodesix
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.